secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001171843-25-002027
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux
--------------------------------------------------------------------------------

- Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.
- Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.
- Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.
- If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.
- Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/f8k_040325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer